"Hydroxamic Acids" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of weak acids with the general formula R-CONHOH.
| Descriptor ID |
D006877
|
| MeSH Number(s) |
D02.092.570.394 D02.241.511.372
|
| Concept/Terms |
Hydroxamic Acids- Hydroxamic Acids
- Acids, Hydroxamic
- Hydroxamic Acid
- Acid, Hydroxamic
|
Below are MeSH descriptors whose meaning is more general than "Hydroxamic Acids".
Below are MeSH descriptors whose meaning is more specific than "Hydroxamic Acids".
This graph shows the total number of publications written about "Hydroxamic Acids" by people in this website by year, and whether "Hydroxamic Acids" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2013 | 0 | 2 | 2 |
| 2015 | 4 | 1 | 5 |
| 2016 | 0 | 2 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hydroxamic Acids" by people in Profiles.
-
Zhang JH, Mottamal M, Jin HS, Guo S, Gu Y, Wang G, Zhao LM. Design, synthesis and evaluation of belinostat analogs as histone deacetylase inhibitors. Future Med Chem. 2019 11; 11(21):2765-2778.
-
Mazzio EA, Soliman KFA. Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A. Cancer Genomics Proteomics. 2018 Sep-Oct; 15(5):349-364.
-
Mazzio EA, Soliman KF. HTP Nutraceutical Screening for Histone Deacetylase Inhibitors and Effects of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed (Vitis vinifera) in HeLa cells. Cancer Genomics Proteomics. 2017 01 02; 14(1):17-33.
-
Wang S, Clarke PAG, Davis R, Mumuni S, Kwabi-Addo B. Sex steroid-induced DNA methylation changes and inflammation response in prostate cancer. Cytokine. 2016 10; 86:110-118.
-
Li QQ, Hao JJ, Zhang Z, Hsu I, Liu Y, Tao Z, Lewi K, Metwalli AR, Agarwal PK. Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach. Int J Oncol. 2016 Jun; 48(6):2591-607.
-
Nelson J, Roe K, Orillo B, Shi PY, Verma S. Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection. Antiviral Res. 2015 Oct; 122:39-45.
-
Yue P, Lopez-Tapia F, Paladino D, Li Y, Chen CH, Namanja AT, Hilliard T, Chen Y, Tius MA, Turkson J. Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo. Cancer Res. 2016 Feb 01; 76(3):652-63.
-
Devaney JM, Wang S, Furbert-Harris P, Apprey V, Ittmann M, Wang BD, Olender J, Lee NH, Kwabi-Addo B. Genome-wide differentially methylated genes in prostate cancer tissues from African-American and Caucasian men. Epigenetics. 2015; 10(4):319-28.
-
Omotuyi IO, Abiodun MO, Komolafe K, Ejelonu OC, Olusanya O. Curcumin and hydroxamate-derivative (PCI-34058) interfere with histone deacetylase I catalytic core Asp-His charge relay system: atomistic simulation studies. J Mol Model. 2015 May; 21(5):109.
-
Thanapprapasr D, Previs RA, Hu W, Ivan C, Armaiz-Pena GN, Dorniak PL, Hansen JM, Rupaimoole R, Huang J, Dalton HJ, Ali-Fehmi R, Coleman RL, Sood AK. PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. Mol Cancer Ther. 2015 Jun; 14(6):1466-1475.